Overview

Study to Evaluate the Efficacy and Safety of Aripiprazole

Status:
Unknown status
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
- To evaluate the efficacy of flexibly dosed aripiprazole in reducing serious behavioral problems in Asian children and adolescents with a diagnosis of autism spectrum disorder, as measured by change from baseline to endpoint on the irritability subscale of the aberrant behavior checklist (ABC-I). - To evaluate the long-term safety and tolerability of flexibly dosed aripiprazole in the treatment of serious behavioral problems in Asian children and adolescents with a diagnosis of autism spectrum disorder.
Phase:
Phase 4
Details
Lead Sponsor:
Yoo-Sook Joung
Collaborator:
Korea Otsuka International Asia Arab
Treatments:
Aripiprazole